Unknown

Dataset Information

0

Anti-Cancer Properties of Two Intravenously Administrable Curcumin Formulations as Evaluated in the 3D Patient-Derived Cancer Spheroid Model.


ABSTRACT: Curcumin (Cur) is a heavily used complementary derived drug from cancer patients. Spheroid samples derived from 82 patients were prepared and treated after 48 h with two Cur formulations (CurA, CurB) in mono- and combination therapy. After 72 h, cell viability and morphology were assessed. The Cur formulations had significant inhibitory effects of -8.47% (p < 0.001), CurA of -10.01% (-50.14-23.11%, p = 0.001) and CurB of -6.30% (-33.50-19.30%, p = 0.006), compared to their solvent controls Polyethylene-glycol, β-Cyclodextrin (CurA) and Kolliphor-ELP, Citrate (CurB). Cur formulations were more effective in prostate cancer (-19.54%) and less effective in gynecological non-breast cancers (0.30%). CurA showed better responses in samples of patients <40 (-13.81%) and >70 years of age (-17.74%). CurB had stronger effects in metastasized and heavily pretreated tumors. Combinations of Cur formulations and standard therapies were superior in 20/47 samples (42.55%) and inferior in 7/47 (14.89%). CurB stimulated chemo-doublets more strongly than monotherapies (-0.53% vs. -6.51%, p = 0.022) and more effectively than CurA (-6.51% vs. 3.33%, p = 0.005). Combinations of Cur formulations with Artesunate, Resveratrol and vitamin C were superior in 35/70 (50.00%) and inferior in 16/70 (22.86%) of samples. Cur formulations were significantly enhanced by combination with Artesunate (p = 0.020). Cur formulations showed a high variance in their anti-cancer effects, suggesting a need for individual testing before administration.

SUBMITTER: Niederreiter M 

PROVIDER: S-EPMC11313667 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-Cancer Properties of Two Intravenously Administrable Curcumin Formulations as Evaluated in the 3D Patient-Derived Cancer Spheroid Model.

Niederreiter Marlene M   Klein Julia J   Schmitz Sebastian B M SBM   Werner Jens J   Mayer Barbara B  

International journal of molecular sciences 20240805 15


Curcumin (Cur) is a heavily used complementary derived drug from cancer patients. Spheroid samples derived from 82 patients were prepared and treated after 48 h with two Cur formulations (CurA, CurB) in mono- and combination therapy. After 72 h, cell viability and morphology were assessed. The Cur formulations had significant inhibitory effects of -8.47% (<i>p</i> < 0.001), CurA of -10.01% (-50.14-23.11%, <i>p</i> = 0.001) and CurB of -6.30% (-33.50-19.30%, <i>p</i> = 0.006), compared to their s  ...[more]

Similar Datasets

| S-EPMC4492550 | biostudies-literature
2023-01-21 | GSE223195 | GEO
| S-EPMC4159185 | biostudies-literature
| S-EPMC4669124 | biostudies-literature
| S-EPMC6337497 | biostudies-literature
| S-EPMC9331260 | biostudies-literature
| S-EPMC7805020 | biostudies-literature
| S-EPMC8399809 | biostudies-literature
| S-EPMC6333502 | biostudies-literature
| S-EPMC10281737 | biostudies-literature